Is your diabetes or obesity drug ready to lead the way?

Innovation in QT Strategies: Leveraging Early-stage Safety Methodologies and AI to Maximize Your Opportunity for a TQT Waiver Webinar Replay

Your treatment for depression could change lives

Can your Parkinson’s drug improve a patients’ symptoms?

Clario and PathAI Collaborate to Deliver Integrated Solution for GI Clinical Trials

Advancing MS Clinical Trials: Integrating Medical Imaging, Precision Motion Analysis, and eCOA Data for Enhanced Outcomes Webinar replay

Psychiatric Drug Development: Digital Endpoint Solutions to Extract the Most Value from Your Clinical Study

Sustainability

We are committed to behaving in the most ethical and sustainable ways possible. Rooted in specific United Nations Sustainable Development Goals (SDGs), our Strategic Sustainability Action Plan guides us every step of the way.

Clario joins forces with Mobilise-D to advance Digital Mobility Outcomes in clinical trials

Advancing MS Clinical Trials: Integrating Medical Imaging, Precision Motion Analysis, and eCOA Data for Enhanced Outcomes

European Respiratory Society (ERS) 2024

Precision Motion for Research

The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights. […]

Read More… from Precision Motion for Research

Advancing Alzheimer’s Clinical Trial Endpoints: Imaging Biomarkers, COA Challenges, Movement Measures, and CV Risk

Clario awarded SAS Global Service Provider Partner of the Year

Ophthalmology

Advance ophthalmic therapeutic from study start-up to regulatory submission with proven site support, project management, and medical expertise. […]

Read More… from Ophthalmology